ArticleBMC cardiovascular disorders2026
Predictive value of combined TyG-BMI and hsCRP for clinical outcomes in patients with chronic coronary syndrome undergoing PCI: a retrospective cohort study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThis retrospective cohort study investigated the joint prognostic value of the triglyceride glucose-body mass index (TyG-BMI) and high-sensitivity C-reactive protein (hsCRP) for post-PCI adverse outcomes in patients with chronic coronary syndromes (CCS) undergoing percutaneous coronary intervention (PCI).
methodsA total of 2274 patients were enrolled and categorized into TyG-BMI tertiles (T1-T3), and were further stratified by hsCRP levels (≤ 3 vs. > 3 mg/L). The primary endpoint was a composite of repeat revascularization or in-stent restenosis (ISR). Cox regression, restricted cubic spline, joint stratification, interaction, sensitivity, and time-specific analyses were performed, including an analysis censored at 12 months and a 1-year landmark analysis.
resultsOver a median follow-up of 60.5 months, 1054 patients (46.4%) experienced the primary endpoint. Each 100-unit increase in TyG-BMI was associated with a 30.8% higher risk of the composite endpoint (adjusted HR 1.308, 95% CI 1.106–1.546; P = 0.002), with a linear association observed across the TyG-BMI range. Compared with T1, patients in T3 had a significantly higher risk of the composite endpoint (adjusted HR 1.263, 95% CI 1.086–1.468; P = 0.002). In cross-stratified analyses, hsCRP > 3 mg/L was associated with a higher risk only in the T3 group (adjusted HR 1.325, 95% CI 1.082–1.623; P = 0.006). Compared with patients in TyG-BMI T1 and hsCRP ≤ 3 mg/L, those in TyG-BMI T3 and hsCRP > 3 mg/L had a 52.3% higher risk of the composite endpoint (adjusted HR 1.523, 95% CI 1.239–1.872; P < 0.001). No significant multiplicative or additive interaction between TyG-BMI and hsCRP was detected. In time-specific analyses, this combined high-risk subgroup showed a modest association with events within the first year after PCI, whereas in the 1-year landmark analysis it remained at the highest risk of the composite endpoint beyond 1 year (adjusted HR 1.569, 95% CI 1.218–2.021; P < 0.001).
conclusionConcurrent elevation of TyG-BMI and hsCRP identifies a subgroup of CCS patients at particularly high risk of repeat revascularization or ISR after PCI. Combined assessment of these two markers may provide complementary prognostic information after PCI, particularly for identifying longer-term residual risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.